Therapy for lower-risk MDS |
Dec 2020 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome |
Dec 2019 |
Hematology. American Society of Hematology. Education Program |
Aplastic Anemia |
Existing agents, novel agents, or transplantation for high-risk MDS |
Dec 2020 |
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
Myelodysplastic syndromes with ring sideroblasts |
Oct 2023 |
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival |
Jul 2020 |
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
Controversies on the Consequences of Iron Overload and Chelation in MDS |
May 2020 |
HemaSphere |
Myelodysplastic Syndromes (MDS) |
Use of Immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis |
Apr 2019 |
Haemotologica |
Myelodysplastic Syndromes (MDS) |
Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria. |
Mar 2019 |
Haematologica |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag |
Apr 2021 |
Haematologica |
Aplastic Anemia |
To Target the Untargetable: Elucidation of Synergy of APR-246 and Azacitidine in TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia |
Jun 2020 |
Haematologica |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |